(Q33897239)

29 July 2017

1 reference

title

Docetaxel: an update of its use in advanced breast cancer (English)

1 reference

29 July 2017

1 reference

D P Figgitt

1

1 reference

29 July 2017

L R Wiseman

series ordinal

2

1 reference

29 July 2017

publication date

1 March 2000

1 reference

29 July 2017

1 reference

29 July 2017

volume

59

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

621-651

1 reference

Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis.

29 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200059030-00015

Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide

21 January 2018

1 reference

12 December 2020

[Preoperative chemotherapy of breast carcinoma]

1 reference

12 December 2020

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

1 reference

12 December 2020

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

1 reference

12 December 2020

Antitumor activity of docetaxel

1 reference

12 December 2020

Clinical pharmacokinetics of docetaxel.

1 reference

12 December 2020

A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC

1 reference

12 December 2020

Docetaxel is a potent cytotoxic drug in the treatment of advanced breast cancer.

1 reference

12 December 2020

Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP)

1 reference

12 December 2020

Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.

1 reference

12 December 2020

Is there a place for "dose-dense" weekly schedules of the taxoids?

1 reference

12 December 2020

A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer

1 reference

12 December 2020

Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel

1 reference

12 December 2020

Key issues in the treatment of advanced breast cancer. Expectations and outcomes

1 reference

12 December 2020

1 reference

12 December 2020

Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere)

1 reference

12 December 2020

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

1 reference

12 December 2020

Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer

1 reference

12 December 2020

Comprehensive criteria for assessing therapy-induced toxicity

1 reference

12 December 2020

Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer

1 reference

12 December 2020

Current management of metastatic breast cancer

1 reference

12 December 2020

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

1 reference

12 December 2020

Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience

1 reference

12 December 2020

Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro

1 reference

12 December 2020

A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer

1 reference

12 December 2020

Docetaxel enhances tumor radioresponse in vivo

1 reference

12 December 2020

Response to dexamethasone in patients with fluid retention after docetaxel

1 reference

12 December 2020

Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel

1 reference

12 December 2020

[An early phase II clinical study of RP56976 (docetaxel) in patients with breast cancer]

1 reference

12 December 2020

Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer

1 reference

12 December 2020

Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers

1 reference

12 December 2020

Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic properties of docetaxel: results of phase I and phase II trials

1 reference

12 December 2020

Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer

1 reference

12 December 2020

Pharmacokinetics of the taxanes

1 reference

12 December 2020

Synergistic and antagonistic interactions between docetaxel and interferon-beta on growth of human breast cancer cells in vitro.

1 reference

12 December 2020

The effect of pretreatment with docetaxel (taxotere; RP 56976) on irradiated subcutaneous MA 16/C murine tumors

1 reference

12 December 2020

Pharmacokinetics and metabolism of Taxotere (docetaxel).

1 reference

12 December 2020

Evaluation of the linearity of docetaxel pharmacokinetics.

1 reference

12 December 2020

Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2

1 reference

12 December 2020

Update on the management of advanced breast cancer.

1 reference

12 December 2020

Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein

1 reference

12 December 2020

Docetaxel (Taxotere): a new option for the treatment of hormone-refractory prostate cancer. Proceedings of a symposium. Chicago, Illinois, USA. April 23, 1999

1 reference

12 December 2020

Docetaxel chemotherapy induces transverse superficial loss of the nail plate

1 reference

12 December 2020

Docetaxel chronopharmacology in mice

1 reference

12 December 2020

1 reference

12 December 2020

A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer

1 reference

12 December 2020

The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer

1 reference

12 December 2020

Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.

1 reference

12 December 2020

Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol

1 reference

12 December 2020

The taxoids. Comparative clinical pharmacology and therapeutic potential

1 reference

12 December 2020

Docetaxel-induced subungual hemorrhage

1 reference

12 December 2020

Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group

1 reference

12 December 2020

Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group.

1 reference

12 December 2020

Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer

1 reference

12 December 2020

Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer

1 reference

12 December 2020

Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group

1 reference

12 December 2020

Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study

1 reference

12 December 2020

Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings.

1 reference

12 December 2020

A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer

1 reference

12 December 2020

Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients.

1 reference

12 December 2020

Systemic Therapy of Advanced Breast Cancer

1 reference

12 December 2020

Breast cancer therapies in development. A review of their pharmacology and clinical potential.

1 reference

12 December 2020

Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients

1 reference

12 December 2020

A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer

1 reference

12 December 2020

Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes.

1 reference

12 December 2020

Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations

1 reference

12 December 2020

Bcl2 is the guardian of microtubule integrity

1 reference

12 December 2020

Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment

1 reference

12 December 2020

A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine

1 reference

12 December 2020

Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer

1 reference

12 December 2020

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

1 reference

12 December 2020

Reporting results of cancer treatment

1 reference

12 December 2020

Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer

1 reference

12 December 2020

Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.

1 reference

12 December 2020

Effects of Taxotere on murine and human tumor cell lines

1 reference

12 December 2020

1 reference

12 December 2020

Recent progress in the clinical development of docetaxel (Taxotere).

1 reference

12 December 2020

Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer

1 reference

12 December 2020

Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion

1 reference

12 December 2020

The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study

1 reference

12 December 2020

The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication

1 reference

12 December 2020

Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer

1 reference

12 December 2020

Combination of taxanes with radiation: preclinical studies

1 reference

12 December 2020

Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion

1 reference

12 December 2020

Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer

1 reference

12 December 2020

Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG).

1 reference

12 December 2020

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

12 December 2020

Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics

1 reference

12 December 2020

Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel.

1 reference

12 December 2020

Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer

1 reference

12 December 2020

Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines

1 reference

12 December 2020

Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer

1 reference

12 December 2020

10.2165/00003495-200059030-00015

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1031084183

0 references

1 reference